Ziprasidone compared with other antipsychotic medicines in schizophrenia
About this title
Read the official source — NCT00159770Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Aalborg and 42 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 290
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Behavioural, Drug, Procedure
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Switzerland, Denmark, Finland, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00159770
- Official title
Show the full official title
Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Aalborg, Denmark · Arhus C, Denmark · Augustenborg, Denmark
40 more locations
- Ballerup Municipality, Denmark
- Brovst, Denmark
- Copenhagen, Denmark
- Dianalund, Denmark
- Esbjerg, Denmark
- Esbjerg N, Denmark
- Glostrup Municipality, Denmark
- Haderslev, Denmark
- Holbæk, Denmark
- Kjellerup, Denmark
- Kolding, Denmark
- København S, Denmark
- Lemvig, Denmark
- Odense C, Denmark
- Ringkøbing, Denmark
- Risskov, Denmark
- Vejle, Denmark
- Viborg, Denmark
- Vordingborg, Denmark
- Forssa, Finland
- Helsinki, Finland
- Jarvenpaa, Finland
- Kiviranta, Finland
- Mikkeli, Finland
- Turku, Finland
- Tuusula, Finland
- Reykjavik, Iceland
- Basel, Switzerland
- Bern, Switzerland
- Sankt Gallen, Switzerland
- Lausanne, Switzerland
- Prangins, Switzerland
- Zurich, Switzerland
- Bulle, Switzerland
- Chêne-Bourg, Switzerland
- Delémont, Switzerland
- Oetwil, Switzerland
- Riehen, Switzerland
- Saint Urban, Switzerland
- Solothurn, Switzerland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including ziprasidone versus olanzapine , risperidone or quetiapine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
